Ticagrelor contraindications: Difference between revisions
(Created page with "__NOTOC__ {{Ticagrelor}} {{CMG}}; {{AE}} {{JH}} ==Contraindications== 4.1 History of Intracranial Hemorrhage BRILINTA is contraindicated in patients with a history of int...") |
No edit summary |
||
| Line 5: | Line 5: | ||
==Contraindications== | ==Contraindications== | ||
===4.1 History of Intracranial Hemorrhage=== | |||
BRILINTA is contraindicated in patients with a history of [[intracranial hemorrhage]] (ICH) because of a high risk of recurrent ICH in this population [see Clinical Studies (14)]. | BRILINTA is contraindicated in patients with a history of [[intracranial hemorrhage]] (ICH) because of a high risk of recurrent ICH in this population [see Clinical Studies (14)]. | ||
4.2 Active Bleeding | ===4.2 Active Bleeding=== | ||
BRILINTA is contraindicated in patients with active pathological bleeding such as peptic ulcer or [[intracranial hemorrhage]] [see Warnings and Precautions (5.1) and Adverse Reactions (6.1)]. | BRILINTA is contraindicated in patients with active pathological bleeding such as peptic ulcer or [[intracranial hemorrhage]] [see Warnings and Precautions (5.1) and Adverse Reactions (6.1)]. | ||
4.3 Severe Hepatic Impairment | ===4.3 Severe Hepatic Impairment=== | ||
BRILINTA is contraindicated in patients with severe hepatic impairment because of a probable increase in exposure, and it has not been studied in these patients. Severe hepatic impairment increases the risk of bleeding because of reduced synthesis of | |||
BRILINTA is contraindicated in patients with severe hepatic impairment because of a probable increase in exposure, and it has not been studied in these patients. Severe hepatic impairment increases the risk of bleeding because of reduced synthesis of coagulation proteins [see Clinical Pharmacology (12.3)]. | |||
===4.4 Hypersensitivity=== | |||
BRILINTA is contraindicated in patients with hypersensitivity (e.g. [[angioedema]]) to ticagrelor or any component of the product [see Adverse Reactions (6.2)]. <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = BRILINTA (TICAGRELOR) TABLET [ASTRAZENECA LP] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f7b3f443-e83d-4bf2-0e96-023448fed9a8 | publisher = | date = | accessdate = 26 February 2014 }}</ref> | |||
BRILINTA is contraindicated in patients with hypersensitivity (e.g. [[angioedema]]) to ticagrelor or any component of the product [see Adverse Reactions (6.2)]. | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
Revision as of 22:41, 28 February 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Jesus Rosario Hernandez, M.D. [2]
Contraindications
4.1 History of Intracranial Hemorrhage
BRILINTA is contraindicated in patients with a history of intracranial hemorrhage (ICH) because of a high risk of recurrent ICH in this population [see Clinical Studies (14)].
4.2 Active Bleeding
BRILINTA is contraindicated in patients with active pathological bleeding such as peptic ulcer or intracranial hemorrhage [see Warnings and Precautions (5.1) and Adverse Reactions (6.1)].
4.3 Severe Hepatic Impairment
BRILINTA is contraindicated in patients with severe hepatic impairment because of a probable increase in exposure, and it has not been studied in these patients. Severe hepatic impairment increases the risk of bleeding because of reduced synthesis of coagulation proteins [see Clinical Pharmacology (12.3)].
4.4 Hypersensitivity
BRILINTA is contraindicated in patients with hypersensitivity (e.g. angioedema) to ticagrelor or any component of the product [see Adverse Reactions (6.2)]. [1]
References
- ↑ "BRILINTA (TICAGRELOR) TABLET [ASTRAZENECA LP]". Retrieved 26 February 2014.